Transduced Dendritic Cells Antigen HER2 Using Retrovirally Clones Specific for the Tumor-Associated The Generation of Both T Killer and Th Cell

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

  2000cited by this paper
• Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A31

  2000cited by this paper
• A HER2/neu-derived peptide, a K[d]-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8[+] cytotoxic T lymphocytes

  2000cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression.

  2000cited by this paper
• Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma

  2000cited by this paper
• Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.

  2000cited by this paper
• CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

  2000cited by this paper
• Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma

  2000cited by this paper
• Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells1

  2000cited by this paper
• Human Monocyte–Derived Dendritic Cells Induce Naive T Cell Differentiation into T Helper Cell Type 2 (Th2) or Th1/Th2 Effectors

  2000cited by this paper
• Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules

  2000cited by this paper
• The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells.

  2000cited by this paper
• A HER2/NEU‐derived peptide, a Kd‐restricted murine tumor rejection antigen, induces HER2‐specific HLA‐A2402‐restricted CD8+ cytotoxic T lymphocytes

  2000cited by this paper
• Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo1

  2000cited by this paper
• Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses1

  2000cited by this paper
• Enrichment and detection of live antigen‐specific CD4+ and CD8+ T cells based on cytokine secretion

  1999cited by this paper
• CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

  1999cited by this paper
• Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

  1999cited by this paper
• Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.

  1999cited by this paper
• Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.

  1999cited by this paper
• Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes

  1999cited by this paper
• The makings of a tumor rejection antigen.

  1999cited by this paper
• Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo

  1999cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• A new era for cancer immunotherapy based on the genes that encode cancer antigens.

  1999cited by this paper
• Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.

  1999cited by this paper
• A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

  1998cited by this paper
• Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.

  1998cited by this paper
• Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes

  1998cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors

  1998cited by this paper
• Help for cytotoxic-T-cell responses is mediated by CD40 signalling

  1998cited by this paper
• Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.

  1998cited by this paper
• The role of CD4+ T cell responses in antitumor immunity.

  1998cited by this paper
• The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

  1998cited by this paper
• Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

  1998cited by this paper
• HER-2/neu oncogenic protein: issues in vaccine development.

  1998cited by this paper
• Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

  1998cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.

  1998cited by this paper
• Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

  1998cited by this paper
• Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under FCS-free conditions: effect of culture conditions on the type of T cell response

  1997cited by this paper
• Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

  1997cited by this paper
• Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity.

  1997cited by this paper
• Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.

  1997cited by this paper
• Cancer Tumor antigens.

  1997cited by this paper
• Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.

  1997cited by this paper
• Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.

  1996cited by this paper
• Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.

  1996cited by this paper
• Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo

  1996cited by this paper
• Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

  1996cited by this paper
• Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ

  1996cited by this paper
• Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo

  1996cited by this paper
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).

  1996cited by this paper
• Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.

  1996cited by this paper
• Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

  1995cited by this paper
• Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood.

  1995cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

  1994cited by this paper
• Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

  1994cited by this paper
• Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones

  1994cited by this paper
• Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

  1994cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues

  1993cited by this paper
• Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.

  1993cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Amplification of c-erbB-2 and aggressive human breast tumors?

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

  1985cited by this paper
• A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17.

  1980cited by this paper

• No citing papers are available for this paper.